Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Camurus AB (CAMX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.060x
Based on the latest financial reports, Camurus AB (CAMX) has a cash flow conversion efficiency ratio of 0.060x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr255.43 Million) by net assets (Skr4.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Camurus AB - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Camurus AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Camurus AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Camurus AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Land and Houses Public Company Limited
OTCGREY:LDHOF
|
0.015x |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
0.035x |
|
BRDNF
PINK:BRDNF
|
N/A |
|
Chengdu Wintrue Holding Co Ltd
SHE:002539
|
-0.032x |
|
Shanghai Phichem Material Co Ltd Class A
SHE:300398
|
0.030x |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
-0.088x |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
-0.034x |
|
Carmila SA
PA:CARM
|
0.031x |
Annual Cash Flow Conversion Efficiency for Camurus AB (2012–2025)
The table below shows the annual cash flow conversion efficiency of Camurus AB from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.24 Billion | Skr869.30 Million | 0.205x | +74.02% |
| 2024-12-31 | Skr3.29 Billion | Skr387.99 Million | 0.118x | -70.98% |
| 2023-12-31 | Skr1.49 Billion | Skr606.88 Million | 0.406x | +299.53% |
| 2022-12-31 | Skr994.67 Million | Skr101.20 Million | 0.102x | +160.22% |
| 2021-12-31 | Skr848.91 Million | Skr-143.43 Million | -0.169x | +40.05% |
| 2020-12-31 | Skr847.44 Million | Skr-238.83 Million | -0.282x | +55.98% |
| 2019-12-31 | Skr631.63 Million | Skr-404.36 Million | -0.640x | +41.06% |
| 2018-12-31 | Skr252.32 Million | Skr-274.08 Million | -1.086x | -105.94% |
| 2017-12-31 | Skr385.00 Million | Skr-203.07 Million | -0.527x | -43.27% |
| 2016-12-31 | Skr564.42 Million | Skr-207.79 Million | -0.368x | -4068.62% |
| 2015-12-31 | Skr640.56 Million | Skr-5.66 Million | -0.009x | -101.57% |
| 2014-12-31 | Skr123.46 Million | Skr69.43 Million | 0.562x | -82.74% |
| 2013-12-31 | Skr50.05 Million | Skr163.06 Million | 3.258x | +429.67% |
| 2012-12-31 | Skr40.21 Million | Skr24.73 Million | 0.615x | -- |